• Stable financial results with maintenance of the cash horizon into mid-2015 • Clinical and pre-clinical programs progressing on track • Strengthening of the Supervisory board and of the Scientific...

All proposed resolutions were voted according to management’s recommendations Pr. Michael Caligiuri was appointed as a new member of the Supervisory Board Innate Pharma (Euronext Paris: FR0010331421 –...

Innate Pharma (Euronext Paris: FR0010331421 – IPH) will hold its Annual General Meeting of Shareholders (“AGM”) on June 28, 2013, at 9:30 am in its headquarters, 117 avenue de Luminy, F-13009...

Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH), the innate immunity company developing first-in-class drugs for cancer and inflammatory diseases, announces revenue of 2.7...

Innate Pharma SA (Euronext Paris: FR0010331421 – IPH), the innate immunity company developing first-in-class drugs for cancer and inflammatory diseases, announces today that new preclinical data for...

Three clinical trials initiated with anti-KIR antibody lirilumab (IPH2102/BMS-986015), including a Phase II trial IPH2201/NN8765 Phase I clinical trial enrolling patients IPH33 drug candidate selected...

Revenue of 14.3 million euros including payments from Bristol-Myers Squibb and research tax credit Strong cash position with 32.6 million euros in cash, cash equivalents and current financial...

A Phase I study of the anti-KIR antibody IPH2102/BMS-986015 in combination with ipilimumab in patients with selected advanced solid tumors published on ClinicalTrials.gov Innate Pharma SA (the...

Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH), the innate immunity company developing first-in-class drugs for cancer and inflammatory diseases, today announces that the first...

Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH), the innate immunity company developing first-in-class drugs for cancer and inflammatory diseases, updates on four early clinical...